NASDAQ:ONTX Onconova Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Onconova Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.37 +0.06 (+4.58%) (As of 07/7/2022 12:22 PM ET) Add Compare Share Today's Range$1.32▼$1.3750-Day Range$1.04▼$1.4452-Week Range$1.00▼$6.77Volume590 shsAverage Volume74,674 shsMarket Capitalization$28.63 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Onconova Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside657.6% Upside$10.00 Price TargetShort InterestHealthy0.09% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.34Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.79) to ($0.74) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.67 out of 5 starsMedical Sector789th out of 1,433 stocksPharmaceutical Preparations Industry402nd out of 683 stocks 3.5 Analyst's Opinion Consensus RatingOnconova Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.00, Onconova Therapeutics has a forecasted upside of 657.6% from its current price of $1.32.Amount of Analyst CoverageOnconova Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.09% of the outstanding shares of Onconova Therapeutics have been sold short.Short Interest Ratio / Days to CoverOnconova Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Onconova Therapeutics has recently decreased by 72.19%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldOnconova Therapeutics does not currently pay a dividend.Dividend GrowthOnconova Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ONTX. Previous Next 1.9 News and Social Media Coverage News SentimentOnconova Therapeutics has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Onconova Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for ONTX on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Onconova Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Onconova Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.20% of the stock of Onconova Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 11.53% of the stock of Onconova Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Onconova Therapeutics are expected to grow in the coming year, from ($0.79) to ($0.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Onconova Therapeutics is -1.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Onconova Therapeutics is -1.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOnconova Therapeutics has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ONTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Onconova Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address About Onconova Therapeutics (NASDAQ:ONTX) StockOnconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company develops a Phase Ib/II ISS with rigosertib monotherapy in patients with advanced squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa; and has a preclinical program comprising IV/oral rigosertib for COVID-19. It has a license agreement with SymBio Pharmaceuticals Limited; license, development, and commercialization agreement with Pint International SA.; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.Read More ONTX Stock News HeadlinesJuly 5, 2022 | americanbankingnews.comOnconova Therapeutics (NASDAQ:ONTX) Shares Pass Above 50-Day Moving Average of $1.25June 28, 2022 | americanbankingnews.comOnconova Therapeutics (NASDAQ:ONTX) Now Covered by Analysts at StockNews.comJune 13, 2022 | seekingalpha.comOnconova Therapeutics appoints company's CFO Mark Guerin as the new COOJune 13, 2022 | finance.yahoo.comOnconova Therapeutics Announces Key Management PromotionsMay 26, 2022 | finance.yahoo.comOnconova Therapeutics Announces Abstract at the ASCO Annual Meeting Highlighting Narazaciclib’s Differentiated Inhibitory and Improved Safety Profile in Preclinical ModelsMay 15, 2022 | finance.yahoo.comIs Onconova Therapeutics (NASDAQ:ONTX) In A Good Position To Deliver On Growth Plans?May 12, 2022 | seekingalpha.comOnconova Therapeutics, Inc. (ONTX) CEO Steve Fruchtman on Q1 2022 Results - Earnings Call TranscriptMay 11, 2022 | finance.yahoo.comOnconova Therapeutics Reports First Quarter 2022 Financial Results and Provides Business UpdateMay 10, 2022 | finance.yahoo.comCollegium Pharmaceutical (COLL) Lags Q1 Earnings EstimatesMay 4, 2022 | finance.yahoo.comOnconova Therapeutics to Provide Corporate Update and Announce First Quarter Financial Results on May 11, 2022May 3, 2022 | finance.yahoo.comOnconova (ONTX) to Report Q1 Earnings: What's in the Cards?May 3, 2022 | finance.yahoo.comOnconova (ONTX) to Report Q1 Earnings: What's in the Cards?April 27, 2022 | finance.yahoo.comOnconova Therapeutics Announces Acceptance of Abstract for Publication at the ASCO Annual MeetingMarch 31, 2022 | finance.yahoo.comCorcept (CORT) Posts OS Data from Phase II Ovarian Cancer StudyMarch 17, 2022 | benzinga.comRecap: Onconova Therapeutics Q4 EarningsMarch 17, 2022 | seekingalpha.comOnconova Therapeutics GAAP EPS of -$0.96 misses by $0.04, revenue of $0.23M in-lineMarch 17, 2022 | finance.yahoo.comOnconova Therapeutics Reports Full Year 2021 Financial Results and Provides Business UpdateMarch 16, 2022 | seekingalpha.comOnconova Therapeutics FY Earnings PreviewMarch 10, 2022 | finance.yahoo.comOnconova Therapeutics to Provide Corporate Update and Announce Fourth Quarter and Full Year 2021 Financial Results on March 17, 2022February 2, 2022 | finance.yahoo.comOnconova Therapeutics to Present at the Guggenheim Oncology ConferenceJanuary 9, 2022 | nasdaq.comOnconova Therapeutics Inc Shares Near 52-Week Low - Market MoverJanuary 4, 2022 | nasdaq.comOnconova Therapeutics Inc Shares Close the Day 10.6% Higher - Daily WrapJanuary 4, 2022 | finance.yahoo.comOnconova Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual ConferenceDecember 13, 2021 | finance.yahoo.comOnconova Therapeutics Appoints Adar Makovski Silverstein, Ph.D., as Director, Corporate DevelopmentDecember 6, 2021 | nasdaq.comOnconova Therapeutics (NASDAQ:ONTX) Is In A Good Position To Deliver On Growth PlansSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ONTX CUSIPN/A CIK1130598 Webwww.onconova.com Phone(267) 759-3680Fax267-759-3681Employees14Year FoundedN/ACompany Calendar Last Earnings5/11/2022Today7/07/2022Next Earnings (Estimated)8/11/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$10.00 High Stock Price Forecast$12.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+629.9%Consensus RatingBuy Rating Score (0-4)3 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.85) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,160,000.00 Net Margins-6,889.38% Pretax Margin-6,889.38% Return on Equity-36.41% Return on Assets-29.48% Debt Debt-to-Equity RatioN/A Current Ratio8.64 Quick Ratio8.64 Sales & Book Value Annual Sales$230,000.00 Price / Sales124.49 Cash FlowN/A Price / Cash FlowN/A Book Value$2.22 per share Price / Book0.62Miscellaneous Outstanding Shares20,900,000Free Float20,645,000Market Cap$28.63 million OptionableNot Optionable Beta1.61 Onconova Therapeutics Frequently Asked Questions Should I buy or sell Onconova Therapeutics stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Onconova Therapeutics stock. View analyst ratings for Onconova Therapeutics or view top-rated stocks. What is Onconova Therapeutics' stock price forecast for 2022? 3 Wall Street analysts have issued 1-year price objectives for Onconova Therapeutics' stock. Their ONTX stock forecasts range from $7.00 to $12.00. On average, they predict Onconova Therapeutics' stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 629.9% from the stock's current price. View analysts' price targets for Onconova Therapeutics or view top-rated stocks among Wall Street analysts. How has Onconova Therapeutics' stock performed in 2022? Onconova Therapeutics' stock was trading at $2.55 on January 1st, 2022. Since then, ONTX shares have decreased by 46.3% and is now trading at $1.37. View the best growth stocks for 2022 here. When is Onconova Therapeutics' next earnings date? Onconova Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022. View our earnings forecast for Onconova Therapeutics. How were Onconova Therapeutics' earnings last quarter? Onconova Therapeutics, Inc. (NASDAQ:ONTX) released its quarterly earnings data on Wednesday, May, 11th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by $0.02. The biopharmaceutical company earned $0.06 million during the quarter, compared to analysts' expectations of $0.06 million. Onconova Therapeutics had a negative trailing twelve-month return on equity of 36.41% and a negative net margin of 6,889.38%. During the same quarter last year, the firm earned ($0.30) earnings per share. View Onconova Therapeutics' earnings history. When did Onconova Therapeutics' stock split? How did Onconova Therapeutics' stock split work? Onconova Therapeutics shares reverse split on the morning of Friday, May 21st 2021. The 1-15 reverse split was announced on Thursday, May 20th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 20th 2021. An investor that had 100 shares of Onconova Therapeutics stock prior to the reverse split would have 7 shares after the split. Who are Onconova Therapeutics' key executives? Onconova Therapeutics' management team includes the following people: Dr. Steven M. Fruchtman M.D., CEO, Pres & Director (Age 71, Pay $903.45k) (LinkedIn Profile)Mr. Mark Patrick Guerin CPA, CFO & COO (Age 53, Pay $578.4k)Dr. Adar Makovski Silverstein Ph.D., Sr. Director & Head of Corp. Devel.Dr. Mark Stephen Gelder M.D., Chief Medical Officer (Age 65) Who are some of Onconova Therapeutics' key competitors? Some companies that are related to Onconova Therapeutics include PDS Biotechnology (PDSB), Gelesis (GLS), Xeris Biopharma (XERS), Decibel Therapeutics (DBTX), Leap Therapeutics (LPTX), Rezolute (RZLT), Daré Bioscience (DARE), DURECT (DRRX), Anebulo Pharmaceuticals (ANEB), Entasis Therapeutics (ETTX), Assembly Biosciences (ASMB), ImmunoPrecise Antibodies (IPA), Cue Biopharma (CUE), Hookipa Pharma (HOOK) and Enochian Biosciences (ENOB). View all of ONTX's competitors. What other stocks do shareholders of Onconova Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Onconova Therapeutics investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), Acasti Pharma (ACST), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Outlook Therapeutics (OTLK) and Actinium Pharmaceuticals (ATNM). What is Onconova Therapeutics' stock symbol? Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX." How do I buy shares of Onconova Therapeutics? Shares of ONTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Onconova Therapeutics' stock price today? One share of ONTX stock can currently be purchased for approximately $1.37. How much money does Onconova Therapeutics make? Onconova Therapeutics (NASDAQ:ONTX) has a market capitalization of $28.63 million and generates $230,000.00 in revenue each year. The biopharmaceutical company earns $-16,160,000.00 in net income (profit) each year or ($0.85) on an earnings per share basis. How many employees does Onconova Therapeutics have? Onconova Therapeutics employs 14 workers across the globe. How can I contact Onconova Therapeutics? Onconova Therapeutics' mailing address is 375 PHEASANT RUN, NEWTOWN PA, 18940. The official website for Onconova Therapeutics is www.onconova.com. The biopharmaceutical company can be reached via phone at (267) 759-3680, via email at ir@onconova.us, or via fax at 267-759-3681. This page (NASDAQ:ONTX) was last updated on 7/7/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
